Clinical Medicine Reviews in Vascular Health

The recent approval of dronedarone by the Food and Drug Administration has expanded the list of drugs available for the treatment of atrial fibrillation (AF). Despite wide-spread attention, the future of this antiarrhythmic compound remains uncertain. The aim of this review is to examine the major clinical trials that have evaluated dronedarone in human subjects and provide a practical framework for its use among patients with AF.